Beyond Estradiol: Why We Monitor FSH in Midlife Women

When we care for women through perimenopause and menopause, one of the questions we continually ask is: How much information do we need to understand what is actually happening in this individual woman?

Guidelines are extraordinarily useful. They establish standards for safe and effective care across large populations. But personalized medicine asks a somewhat different question.

Not simply, What is the minimum information necessary to appropriately prescribe menopausal hormone therapy?

But rather:

What information might help us better understand this woman’s physiology, her trajectory, and the tissues we are trying to protect over the next several decades?

That distinction is why, in our clinic, we often continue to monitor hormones—including FSH—through the menopause transition.

We consider FSH because an increasingly interesting body of research suggests that FSH may tell us something about the biological transition occurring in bone and adipose tissue that estradiol alone does not completely capture.

FSH has traditionally been treated as a messenger

The conventional model is familiar.

As ovarian responsiveness declines, inhibin and estrogen feedback change. The pituitary responds by producing increasing amounts of FSH.

In that model, FSH is essentially the dashboard warning light.

It tells us what is happening at the ovary, but the FSH itself isn’t particularly important.

Over the last two decades, researchers have challenged that assumption.

They have identified FSH receptors outside the ovary—including experimental evidence of functional FSH signaling in bone and adipose tissue.

And that raises a fascinating possibility:

What if the rising FSH of midlife isn’t merely reporting the transition? What if, at least in some tissues, it participates in it?

Bone provides one of the strongest reasons to ask the question

We know that skeletal deterioration doesn’t suddenly begin when estradiol becomes unequivocally low.

Longitudinal SWAN data demonstrate that accelerated bone loss begins before the final menstrual period and reaches its greatest velocity around the menopause transition.

In one longitudinal analysis, lumbar-spine and femoral-neck bone loss began during an FSH-defined stage approximately two years before the final menstrual period.

And another SWAN analysis produced a finding I think deserves much more attention in clinical conversations.

Researchers asked whether reproductive hormones could predict which women were about to begin losing bone.

Every halving of estradiol was associated with a 12% greater likelihood of significant femoral-neck bone loss.

But every doubling of FSH was associated with a 27% greater likelihood.

FSH was particularly informative for identifying the onset of rapid lumbar-spine bone loss.

If a changing biomarker helps identify a changing biological state, we want to understand it.

These experiments provide a plausible biological framework for something clinicians had already observed epidemiologically:

The period of rapidly rising FSH overlaps with the period in which bone loss accelerates.

And then researchers discovered that the same hormone might be doing something in another tissue that changes dramatically during menopause.

Adipose tissue

One of the most frustrating experiences for many women in midlife is a change in body composition that seems disproportionate to changes in their behavior.

Sometimes weight barely changes.

But waist circumference does.

Lean mass decreases.

And visceral adiposity increases.

SWAN has helped characterize this transition remarkably well.

In longitudinal imaging studies, visceral adipose tissue begins accelerating approximately two years before the final menstrual period.

During those two years immediately preceding menopause, VAT increased approximately 8% per year in one SWAN analysis.

That timing is fascinating because it coincides with another endocrine event: the dramatic acceleration of FSH.

Again, correlation is not causation.

But mechanistic research makes the relationship harder to dismiss as biologically irrelevant.

FSH receptors have also been identified in adipose tissue

Experimental studies have reported functional FSH receptors in human and mouse adipocytes.

FSH signaling has been associated with pathways favoring lipid synthesis and storage.

Then came an extraordinary experiment published in Nature.

Researchers blocked FSH signaling in mice.

The animals developed less adipose tissue.

But more importantly, their adipose tissue changed biologically.

There was greater mitochondrial density.

White adipocytes moved toward a beige phenotype.

Brown adipose tissue became more active.

Thermogenesis increased.

In other words, blocking FSH appeared to shift adipose tissue away from energy storage and toward energy expenditure.

Perhaps some of what we have attributed entirely to estrogen withdrawal reflects a broader endocrine transition involving both falling ovarian signals and rising pituitary signals.

And this is where personalized monitoring becomes valuable to us

We are looking at patterns.

It tells us that estradiol concentration and symptom control have not completely described what is happening in this woman’s tissues.

And that is the distinction we are interested in.

We aren’t treating the laboratory. We’re interrogating the physiology.

For us, FSH is one piece of a larger longitudinal picture.

We may look at estradiol and progesterone where clinically relevant.

But we also look at FSH.

We look at bone density.

In selected women, we look at bone-turnover markers such as CTX.

We look at lean mass and visceral adiposity when we have useful ways to measure them.

We look at insulin physiology, glucose, triglycerides, ApoB and other cardiometabolic markers.

We look at muscle strength and exercise.

We look at protein intake.

We look at sleep.

And then we ask:

Is this woman’s physiology moving in the direction we want it to move?

That is very different from chasing an isolated hormone number.

FSH can simultaneously be: a marker of ovarian aging,
a marker associated with impending bone loss,
a potential participant in extra-gonadal signaling,
 and a useful component of a longitudinal endocrine phenotype.

Those aren’t mutually exclusive.

This is where guidelines and personalized care answer different questions

Guidelines appropriately tell clinicians that routine hormone measurements are generally unnecessary for managing menopausal hormone therapy.

If a healthy woman has classic vasomotor symptoms and improves with appropriately prescribed estrogen, we don’t need a laboratory test to prove that she feels better.

But personalized medicine can reasonably ask a deeper question:

Are we optimizing only her symptoms—or are we following the physiology of the transition itself?

Those are not competing philosophies.

They are different levels of resolution.

Personalized care can use those guidelines as its foundation while also asking whether additional biomarkers provide useful information about the individual patient in front of us.

And this changes what we mean by optimization

We don’t define successful menopause therapy as achieving a particular estradiol concentration.

And we don’t define it as suppressing FSH to a particular concentration.

The target is larger.

The target is the woman.

And ultimately, her healthspan.

Hormones are tools that help us understand and influence those outcomes.

They are not themselves the outcome.

So why monitor FSH?

Because it gives us another window.

It may tell us something about where a woman is in the neuroendocrine transition.

It may help identify a period of accelerated skeletal vulnerability.

It may eventually help us understand changes in adipose biology.

And when we follow it longitudinally alongside estradiol, bone, body composition and metabolic markers, it allows us to ask a more sophisticated question than simply:

“Is her estrogen high enough?”

We can ask:

“What is happening to this woman’s physiology over time, and is our strategy adequately protecting the tissues we care about?”

The emerging FSH literature doesn’t give us all the answers.

What it does is give us reason to keep asking the question.

And that, to us, is the value of monitoring.

Because the goal of personalized menopause medicine isn’t to normalize a laboratory value.

It is to use every meaningful piece of information available to help preserve bone, muscle, metabolic health and quality of life across the decades that follow menopause.

Perimenopause is a conversation between the brain and ovaries—and estrogen tells only part of the story. Follicle-stimulating hormone, or FSH, is a signal from the pituitary gland that encourages ovarian follicles to develop. As the ovaries become less responsive, that signal grows louder. FSH can rise while estrogen still looks reassuring on a blood test, offering another window into a transition already underway.

Our aim is to understand your changing physiology early enough to care for your future health, as well as how you feel today.

Warmly,
Rachel